LIVE: New Covid-19 variant triggers global alarm, AstraZeneca takes stock
AstraZeneca said it was examining the impact of a new coronavirus variant that is spreading rapidly in South Africa on its vaccine and its antibody cocktail27-11-2021
27-11-2021
AstraZeneca chief credits Oxford vaccine with UK's Covid-19 fight
Soriot was speaking as his company unveiled a major state-of-the-art research and development facility in Cambridge24-11-2021
India allows export of 20 million Novavax vaccine doses to Indonesia
The government has also decided to allow the export of 10 million doses of a licensed version of the AstraZeneca shot made by SII, which it calls Covishield, to the global vaccine-sharing programme COVAX, two sources said. Shipment is likely to happen towards the end of next month, one of the sources said.19-11-2021
AstraZeneca Pharma India Ltd - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant17-11-2021
AstraZeneca says it will start profiting from its COVID-19 vaccine
To a far greater extent than the vaccines from Pfizer-BioNTech and Moderna, AstraZeneca's vaccine has been the workhorse of the effort to vaccinate poorer countries, many of which are facing severe vaccine shortages. About 1.1 billion AstraZeneca doses had reached low- and lower-middle income countries as of around the end of October13-11-2021
AstraZeneca Pharma India Q2 net profit declines 55% to Rs 12 crore
The company had posted a net profit of Rs 26.33 crore for the corresponding period of the previous financial year, it said in a filing to the BSE.09-11-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Outcome Of The Board Meeting Held On Tuesday, November 9, 2021
At the Board meeting of the Company held on Tuesday, November 9, 2021 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended September 30, 2021. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated November 9, 2021 are enclosed herewith.09-11-2021
US cancels Covid-19 vaccine maker's multimillion dollar deal: Report
The federal government has canceled a multimillion dollar deal with Emergent BioSolutions, a Maryland-based vaccine manufacturer with facilities in Baltimore that were found to have produced millions of contaminated Johnson & Johnson vaccine doses this spring, the Washington Post reported. Emergent disclosed the development Thursday in a conference call discussing its latest financial results, the Post reported. Emergent said it will forgo about USD 180 million due to the contract's termination, according to the Post. Emergent BioSolutions played a role in the Trump administration's effort to speed up vaccine development and distribution. But after winning a contract from the previous administration, Emergent quickly ran into production problems. In March, ingredients intended for use in producing the Oxford-AstraZeneca vaccine shots contaminated 15 million doses of the Johnson & Johnson vaccine. The problems with the vaccines caused a monthslong delay in production. After...05-11-2021
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Tuesday, November 9, 2021
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2021 ,inter alia, to consider and approve This is to inform you that a meeting of the Board of Directors of AstraZeneca Pharma India Limited will be held on Tuesday, November 9, 2021 inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2021 We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from September 16, 2021 to November 11, 2021 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.02-11-2021
WHO chief, Mandaviya talk Covaxin, resuming Covishield supply to COVAX
WHO chief Tedros Adhanom Ghebreyesus discussed the issue of the emergency use listing of Bharat Biotech's COVID-19 vaccine Covaxin and resumption of supplies of the Serum Institute of India-manufactured AstraZeneca vaccine to the COVAX facility among other topics during a telephonic conversation with Health Minister Mansukh Mandaviya. Had a call with @mansukhmandviya, India's Health Minister, to discuss #India's ongoing #COVID19 vaccination programme; the need for a global pandemic agreement; digital health; & traditional medicine. We welcome India's support to strengthen WHO, incl. via flexible, sustainable financing, Ghebreyesus tweeted on Tuesday. The WHO Director-General said that he also discussed with Mandaviya vaccine equity issues: the resumption of SII/AstraZeneca vaccine supplies to #COVAX; the Covaxin Emergency Use Listing process; and technology and license sharing through C-TAP. COVID-19 Technology Access Pool (C-TAP) was launched in May last year for facilitating...21-10-2021